April 24 – Interim report January – March 2025
Alligator hosted a webinar on Thursday, 24 April, at 2 p.m. CEST for investors, analysts and media, where CEO Søren Bregenholt and CFO Johan Giléus presented and commented on the report, which was followed by a Q&A session.
The call was held in English and can be requested through the link below.
LATEST NEWS
Alligator receives positive scientific advice from EMA on Phase 3 trial of mitazalimab
Lund, Sweden, 17 June 2025 — Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing tumor-d …
Alligator Bioscience receives FDA endorsement of mitazalimab Phase 3 dose for pancreatic cancer
Lund, Sweden – 13 June 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing …
Biomarker data from Alligator Bioscience’s OPTIMIZE-1 trial presented at ASCO 2025 Annual Meeting
Lund, Sweden, 3 June 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that biomarker data from its OPTIMIZE-1 cli …